000
| 02560nam 2200385zi 4500 |
---|
001 | 9.914234 |
---|
003 | CaOODSP |
---|
005 | 20230217083031 |
---|
006 | m o d f |
---|
007 | cr mn||||||||| |
---|
008 | 220808t20232023onc ob f000 0 eng d |
---|
020 | |a9780660449388 |
---|
040 | |aCaOODSP|beng|erda|cCaOODSP |
---|
043 | |an-cn--- |
---|
086 | 1 |aHP40-321/2022E-PDF |
---|
245 | 00|aNACI literature review on the effects of palivizumab prophylaxis on reducing the complications associated with respiratory syncytial virus in infants. |
---|
246 | 17|aEffects of palivizumab prophylaxis on reducing complications associated with respiratory syncytial virus in infants |
---|
264 | 1|aOttawa, Ontario : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |c2023. |
---|
264 | 4|c©2023 |
---|
300 | |a1 online resource (133 pages) |
---|
336 | |atext|btxt|2rdacontent |
---|
337 | |acomputer|bc|2rdamedia |
---|
338 | |aonline resource|bcr|2rdacarrier |
---|
500 | |aCover title. |
---|
500 | |a"Publication date: February 2023." |
---|
500 | |aAt head of title: An Advisory Committee Review National Advisory Committee on Immunization (NACI). |
---|
500 | |aIssued also in French under title: Revue de la littérature du CCNI sur les effets de la prophylaxie par palivizumab sur la réduction des complications associées au virus respiratoire syncytial chez les nourrissons. |
---|
504 | |aIncludes bibliographical references (pages 46-50). |
---|
520 | |a"The literature review examined the evidence on the effectiveness of palivizumab (PVZ) prophylaxis compared to the administration of placebo or to no prophylaxis in reducing the complications associated with RSV infection in children. The outcomes of interest included hospitalization, length of hospital stay, stay in intensive care, length of stay (LOS) in intensive care, use of oxygen therapy, length of oxygen therapy use, use of mechanical ventilation (MV), length of MV use, long-term sequelae (e.g., wheezing, asthma), and mortality"--Executive summary, page 6. |
---|
650 | 0|aPalivizumab|zCanada. |
---|
650 | 0|aRespiratory syncytial virus|zCanada. |
---|
650 | 0|aInfants|xDiseases|zCanada. |
---|
710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
---|
775 | 08|tRevue de la littérature du CCNI sur les effets de la prophylaxie par palivizumab sur la réduction des complications associées au virus respiratoire syncytial chez les nourrissons.|w(CaOODSP)9.914235 |
---|
856 | 40|qPDF|s1.54 MB|uhttps://publications.gc.ca/collections/collection_2023/aspc-phac/HP40-321-2022-eng.pdf |
---|